IBCL-492 A Cost-Effectiveness Analysis of Mosunetuzumab for Treatment of Thirdor Higher-Line Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in the United States (US)
Clinical Lymphoma, Myeloma & Leukemia（2023）
关键词
IBCL,mosunetuzumab,cost-effectiveness,relapsed/refractory,follicular lymphoma,United States
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要